Tela Bio Company Insiders
TELA Stock | USD 2.94 0.07 2.33% |
Tela Bio employs about 227 people. The company is managed by 12 executives with a total tenure of roughly 530 years, averaging almost 44.0 years of service per executive, having 18.92 employees per reported executive. Analysis of Tela Bio's management performance can provide insight into the company performance.
Tela Bio's Insider Buying Vs Selling
50
Selling | Buying |
Latest Trades
2024-10-24 | Roberto Cuca | Acquired 64444 @ 2.25 | View | ||
2024-07-01 | Orbimed Advisors Llc | Disposed 13700 @ 4.68 | View | ||
2024-06-28 | Orbimed Advisors Llc | Disposed 378000 @ 4.74 | View | ||
2023-12-05 | Gregory A Firestone | Acquired 2600 @ 5.65 | View |
Monitoring Tela Bio's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Tela |
Tela Bio's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Tela Bio's future performance. Based on our forecasts, it is anticipated that Tela will maintain a workforce of about 230 employees by December 2024.Tela Bio Management Team Effectiveness
The company has return on total asset (ROA) of (0.4064) % which means that it has lost $0.4064 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.4204) %, meaning that it created substantial loss on money invested by shareholders. Tela Bio's management efficiency ratios could be used to measure how well Tela Bio manages its routine affairs as well as how well it operates its assets and liabilities. As of November 26, 2024, Return On Tangible Assets is expected to decline to -0.65. In addition to that, Return On Capital Employed is expected to decline to -0.76. At present, Tela Bio's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 278.2 K, whereas Total Assets are forecasted to decline to about 63.7 M.As of November 26, 2024, Common Stock Shares Outstanding is expected to decline to about 14.3 M. In addition to that, Net Loss is expected to decline to about (41.9 M)
Tela Bio Workforce Comparison
Tela Bio is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 9,379. Tela Bio holds roughly 227 in number of employees claiming about 2.42% of equities under Health Care industry.
Tela Bio Profit Margins
The company has Profit Margin (PM) of (0.6) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.49) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.49.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.47 | 0.6862 |
|
|
Tela Bio Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tela Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tela Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Tela Bio insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-06-01 | 12.0 | 12 | 1 | 67,925 | 378,000 |
2024-03-01 | 0.6111 | 11 | 18 | 380,600 | 23,960 |
2023-09-01 | 0.3333 | 1 | 3 | 17,950 | 47,670 |
2023-06-01 | 4.0 | 12 | 3 | 50,970 | 192,000 |
2023-03-01 | 0.7692 | 10 | 13 | 303,360 | 17,932 |
2022-06-01 | 17.0 | 34 | 2 | 186,600 | 3,502,200 |
2022-03-01 | 2.375 | 38 | 16 | 1,654,284 | 126,787 |
2020-03-01 | 0.5 | 1 | 2 | 60,000 | 0.00 |
2019-12-01 | 0.6615 | 43 | 65 | 7,763,776 | 121,299,052 |
Tela Bio Notable Stakeholders
A Tela Bio stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Tela Bio often face trade-offs trying to please all of them. Tela Bio's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Tela Bio's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Megan Smeykal | Corporate VP | Profile | |
Taylor Ocasio | General Secretary | Profile | |
Antony Koblish | President, Cofounder | Profile | |
Louisa Smith | Investor Officer | Profile | |
Skott Greenhalgh | Chief Officer | Profile | |
Peter Murphy | Chief Officer | Profile | |
Roberto JD | CFO COO | Profile | |
Gregory Firestone | Chief Officer | Profile | |
Michael Leonard | Senior Operations | Profile | |
Jennifer Armstrong | Senior Resources | Profile | |
Paul Talmo | Chief Officer | Profile | |
Christopher Smith | VP Sales | Profile |
About Tela Bio Management Performance
The success or failure of an entity such as Tela Bio often depends on how effective the management is. Tela Bio management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Tela management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Tela management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.61) | (0.65) | |
Return On Capital Employed | (0.72) | (0.76) | |
Return On Assets | (0.60) | (0.63) | |
Return On Equity | (2.47) | (2.60) |
Please note, the presentation of Tela Bio's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Tela Bio's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Tela Bio's management manipulating its earnings.
Tela Bio Workforce Analysis
Traditionally, organizations such as Tela Bio use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Tela Bio within its industry.Tela Bio Manpower Efficiency
Return on Tela Bio Manpower
Revenue Per Employee | 257.5K | |
Revenue Per Executive | 4.9M | |
Net Loss Per Employee | 205.6K | |
Net Loss Per Executive | 3.9M | |
Working Capital Per Employee | 241.2K | |
Working Capital Per Executive | 4.6M |
Complementary Tools for Tela Stock analysis
When running Tela Bio's price analysis, check to measure Tela Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tela Bio is operating at the current time. Most of Tela Bio's value examination focuses on studying past and present price action to predict the probability of Tela Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tela Bio's price. Additionally, you may evaluate how the addition of Tela Bio to your portfolios can decrease your overall portfolio volatility.
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |